Current Concepts in the Surgical Management of Glioma Patients
Overview
Authors
Affiliations
The scientific basis for the surgical management of patients with glioma is rapidly evolving. The infiltrative nature of these cancers precludes a surgical cure, but despite this, cytoreductive surgery remains central to high-quality patient care. In addition to tissue sampling for accurate histopathological diagnosis and molecular genetic characterisation, clinical benefit from decompression of space-occupying lesions and microsurgical cytoreduction has been reported in patients with different grades of glioma. By integrating advanced surgical techniques with molecular genetic characterisation of the disease and targeted radiotherapy and chemotherapy, it is possible to construct a programme of personalised surgical therapy throughout the patient journey. The goal of therapeutic packages tailored to each patient is to optimise patient safety and clinical outcome and must be delivered in a multidisciplinary setting. Here we review the current concepts that underlie surgical subspecialisation in the management of patients with glioma.
Radiological and Not Clinical Variables Guide the Surgical Plan in Patients with Glioblastoma.
Martin-Abreu C, Farina-Jeronimo H, Plata-Bello J Curr Oncol. 2024; 31(4):1899-1912.
PMID: 38668045 PMC: 11049408. DOI: 10.3390/curroncol31040142.
GDNF triggers proliferation of rat C6 glioma cells via the NF-κB/CXCL1 signaling pathway.
Wang Y, Wu Y, Li L, Gao J, Gao D, Sun S PLoS One. 2023; 18(8):e0289071.
PMID: 37594930 PMC: 10437914. DOI: 10.1371/journal.pone.0289071.
G protein inhibitory α subunit 2 is a molecular oncotarget of human glioma.
Wang Y, Liu F, Wu J, Zhang M, Chai J, Cao C Int J Biol Sci. 2023; 19(3):865-879.
PMID: 36778118 PMC: 9909998. DOI: 10.7150/ijbs.79355.
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
Maczynska J, Raes F, Da Pieve C, Turnock S, Boult J, Hoebart J BMC Med. 2022; 20(1):16.
PMID: 35057796 PMC: 8780306. DOI: 10.1186/s12916-021-02213-z.
Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
Kim H, Kim D Molecules. 2020; 25(20).
PMID: 33053763 PMC: 7587213. DOI: 10.3390/molecules25204641.